Skip to main content

Clinical Trial Risk Assessment & Management Plan

BayBiotech.NET

Before the onset of a trial the study director/sponsor must have a risk assessment and risk management plan to accompany the filing to IRB or FDA for IND or PMA applications.
Hazard is defined as anything that could cause harm and risk is the probability of that harm caused by the hazard.
Risk Assessment Plan for each potential hazard includes mapping and analysis of associated risks, its potential consequences and reasonable steps to reduce the risks.

In a clinical trial hazards are categorized into main four groups:

1.    Hazards for the participants that encompasses protecting participant’s rights.
2.    Hazards for the participant’s safety by assessing the likely risk/ benefit ratio in the study population.
3.    Hazards of the trial with risk associated for recruitment and follow-up.
4.    Hazard to the reliability of the results mainly in terms of study power and adherence to the protocol.

Risk Management Plan includes detailed strategies and considerations to reduce/ minimize the above mentioned hazards customized for a particular study.

It will be Study Director/ Sponsor’s responsibility to educate all the professionals involved in the trial to be aware of the Risk Assessment and Management Plan for a successful trial completion.

Comments

Post a Comment

Popular posts from this blog

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Available Total Quality Management Tools

BayBiotech.NET Total Quality Management (or TQM) is a management concept coined by W. Edwards Deming. One of the principal aims of TQM is to limit errors to 1 per 1 million units produced. There are several TQM tools available today to analyze and assess qualitative and quantitative data. These tools can be examined and used to enhance the overall quality of the procedures, products or the work environment. Some of the most common TQM tools in use today are Pie Charts and Bar Graphs, Histograms, Run charts, Pareto Charts, Force Field Analysis, Ishikawa or Fishbone Diagrams, Tree Diagrams, Brainstorming, Flow Charts, Plan-Do-Check-Act cycle and Scatter Diagrams. Proper integration and use of these tools ultimately assist in processing data such as identifying collecting policies, enhancing work flows, ensuring client satisfaction by surveying their needs and analyzing them accordingly and creating an overall high level of quality in all areas of your organization. Use and choice...
Post a Comment
Read more